Advertisement
Loading...

Metis Techbio-p

7666.HKHKSE
Healthcare
Biotechnology
HK$15.00
HK$0.22(1.49%)
Hong Kong Market is Open • 11:16
Advertisement

Metis Techbio-p Fundamental Analysis

Metis Techbio-p (7666.HK) shows weak financial fundamentals with a PE ratio of -41.47, profit margin of -3.73%, and ROE of 2.70%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-3.25
Current Ratio6.67

Areas of Concern

ROE2.70%
Operating Margin-3.67%
Cash Position0.91%
We analyze 7666.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -289.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-289.0/100

We analyze 7666.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

7666.HK struggles to generate sufficient returns from assets.

ROA > 10%
-29.57%

Valuation Score

Excellent

7666.HK trades at attractive valuation levels.

PE < 25
-41.47
PEG Ratio < 2
-3.25

Growth Score

Weak

7666.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

7666.HK maintains a strong and stable balance sheet.

Debt/Equity < 1
0.13
Current Ratio > 1
6.67

Profitability Score

Weak

7666.HK struggles to sustain strong margins.

ROE > 15%
270.37%
Net Margin ≥ 15%
-3.73%
Positive Free Cash Flow
No

Key Financial Metrics

Is 7666.HK Expensive or Cheap?

P/E Ratio

7666.HK trades at -41.47 times earnings. This suggests potential undervaluation.

-41.47

PEG Ratio

When adjusting for growth, 7666.HK's PEG of -3.25 indicates potential undervaluation.

-3.25

Price to Book

The market values Metis Techbio-p at 15.20 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

15.20

EV/EBITDA

Enterprise value stands at -47.84 times EBITDA. This is generally considered low.

-47.84

How Well Does 7666.HK Make Money?

Net Profit Margin

For every $100 in sales, Metis Techbio-p keeps $-3.73 as profit after all expenses.

-3.73%

Operating Margin

Core operations generate -3.67 in profit for every $100 in revenue, before interest and taxes.

-3.67%

ROE

Management delivers $2.70 in profit for every $100 of shareholder equity.

2.70%

ROA

Metis Techbio-p generates $-29.57 in profit for every $100 in assets, demonstrating efficient asset deployment.

-29.57%

Following the Money - Real Cash Generation

Operating Cash Flow

Metis Techbio-p generates limited operating cash flow of $-16.51M, signaling weaker underlying cash strength.

$-16.51M

Free Cash Flow

Metis Techbio-p generates weak or negative free cash flow of $-19.04M, restricting financial flexibility.

$-19.04M

FCF Per Share

Each share generates $-0.02 in free cash annually.

$-0.02

FCF Yield

7666.HK converts -0.89% of its market value into free cash.

-0.89%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-41.47

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-3.25

vs 25 benchmark

P/B Ratio

Price to book value ratio

15.20

vs 25 benchmark

P/S Ratio

Price to sales ratio

150.80

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.13

vs 25 benchmark

Current Ratio

Current assets to current liabilities

6.67

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

2.70

vs 25 benchmark

ROA

Return on assets percentage

-0.30

vs 25 benchmark

ROCE

Return on capital employed

-0.34

vs 25 benchmark

How 7666.HK Stacks Against Its Sector Peers

Metric7666.HK ValueSector AveragePerformance
P/E Ratio-41.4728.32 Better (Cheaper)
ROE270.37%733.00% Weak
Net Margin-373.18%-53055.00% (disorted) Weak
Debt/Equity0.130.38 Strong (Low Leverage)
Current Ratio6.674.03 Strong Liquidity
ROA-29.57%-19488.00% (disorted) Weak

7666.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Metis Techbio-p's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ